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Abstract
The aim of this study was to investigate the relationship between tobacco smoke habit,
patient age, DNA aneuploidy and genomic DNA copy number aberrations (CNAs) in oral
potentially malignant disorder (OPMD) and oral squamous cell carcinoma (OSCC) patients.
DNA aneuploidy was detected by high-resolution DNA flow cytometry (hr DNA-FCM) on
DAPI stained nuclei obtained from multiple tissue samples from OPMDs/OSCCs in 220 con-
secutive patients. Nuclear genomic aberrations were determined in a subset of 65 patients
by genome-wide array comparative genomic hybridization (aCGH) using DNA extracted
from either diploid or aneuploid nuclei suspension sorted by FCM. DNA aneuploidy and
mean nuclear genomic aberrations were associated with patients’ age. In particular, DNA
aneuploidy strongly associated with age in non-smoker OPMDs/OSCCs patients. OSCCs
from smokers showed a lower prevalence of DNA aneuploidy compared to OSCCs from
non-smokers. A higher occurrence of DNA aneuploidy (particularly in smokers’ OPMDs)
was observed in patients characterized by involvement of a single oral subsite. Our study
suggests that: 1) DNA aneuploidy in non-smokers is mainly related to aging; 2) OPMDs/
OSCCs involving multiple oral subsites in smokers are less likely to develop DNA aneu-
ploidy compared to non-smokers; 3) OSCC development is characterized by both CIN and
CIN-independent mechanisms and that the latter are more relevant in smokers. This study
provides evidence that DNA diploid OPMDs may be considered at lower risk of canceriza-
tion than DNA aneuploid ones in non-smokers but not in smokers.
Introduction
Oral potentially malignant disorders (OPMDs) are an heterogeneous group of asymptomatic
mucosal alterations of various etiology associated to alteration of the nuclear genome that may
lead to oral squamous cell carcinomas (OSCCs) [1]. Estimates of the transformation rate of
OPMDs in the literature vary [2] but there is a wide consensus on a frequency of about 1.36%
PLOS ONE | https://doi.org/10.1371/journal.pone.0184425 September 6, 2017 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Castagnola P, Gandolfo S, Malacarne D,
Aiello C, Marino R, Zoppoli G, et al. (2017) DNA
aneuploidy relationship with patient age and
tobacco smoke in OPMDs/OSCCs. PLoS ONE
12(9): e0184425. https://doi.org/10.1371/journal.
pone.0184425
Editor: Bo Hang, Lawrence Berkeley National Lab,
UNITED STATES
Received: February 1, 2017
Accepted: August 23, 2017
Published: September 6, 2017
Copyright: © 2017 Castagnola et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
per year and 95% confidence intervals (CI) between 0.69 and 2.03% [3]. To date, the histologi-
cal detection of dysplasia is the most important criterion followed by oral surgeons to decide
the excision of OPMDs in an effort to prevent OSCCs [4]. However, no clinical studies that
prove the efficacy of this approach have been reported so far. Several studies were conducted
in an effort to find additional criteria that could predict the progression to OSCC of a given
OPMD. Clinical studies showed that some subsites of the oral mucosa, which included tongue
and floor of the mouth, have an increased risk of cancer development [5]. Others found a rela-
tionship of DNA aneuploidy, which reflects chromosomal instability (CIN), with dysplasia [6–
11]. Further studies provided also evidences of an association between DNA aneuploidy with
high-risk oral mucosa subsites [12] and with genomic copy number aberrations [13]. How-
ever, the proof that DNA aneuploidy can predict the progression of given OPMD in a clinical
setting is still missing and the same applies for some molecular markers, such as p53 (TP53),
Cyclin D1, and podoplanin (PDPN), HIF-1alpha, E-cadherin, and p63, which were also inves-
tigated [14, 15].
Tobacco consumption, either chewed or smoked, is recognized as the major risk factor for
OPMDs and OSCCs [16] and is associated to cytotoxic and genotoxic effects [17]. Tobacco
smoke, in particular, contains carcinogens that bind to the DNA generating DNA adducts
[18], which in turn may cause mutations able to activate cellular oncogenes or inactivate
tumor suppressor genes [19, 20]. Additionally, tobacco components are potent free radical
generators, which may cause genotoxic effects by inducing single strand DNA breaks [21]. It
was also shown that tobacco use induces an increase in the number of aneuploid nuclei in the
oral epithelium [22]. However, a recent study indicates that in the oral epithelium tobacco
smoke mainly induces acceleration of cellular mechanisms that in turn lead to genomic DNA
damage [23, 24].
The relationship between aging and DNA aneuploidy has been investigated extensively in
the scientific literature but, as far as we know, poorly in OPMDs and OSCCs. Our previous
study with 60 OPMD patients enrolled, suggested that DNA aneuploidy is an early event in
oral carcinogenesis and that the effects of tobacco smoke is age- and oral subsite-dependent
[25]. The aim of this study was to test these results on a substantially larger OPMDs/OSCCs
patients’ cohort. We took advantage of high resolution DNA flow cytometry (hr DNA-FCM)
of DAPI stained nuclei extracted from tissue samples obtained from OPMDs/OSCCs to deter-
mine the DNA Index (DI) and used logistic regression to evaluate the role of each variable con-
sidered in the study.
Materials and methods
Patients and tissue specimens
Patients with OPMDs or OSCCs were enrolled in the study by the Oral Medicine and Oral
Oncology Unit of the University of Turin at the A.O.U. S. Luigi Gonzaga (Orbassano-Turin).
Written informed consent was obtained from all the enrolled patients as requested by the
Institutional Ethics Committees (A.O.U. S. Luigi Gonzaga Prot. N. 11780), which specifically
approved this study. Protocols included in the Declaration of Helsinki were followed in
designing the study.
Tobacco smoke and alcohol consumption habit were recorded during the interview that
was performed to inform the patient on the aim of the study and to collect the patient’s consent
to participate.
Histological evidence of one or more OPMDs (homogeneous and non-homogeneous leu-
koplakias, erythroplakias and erythroleukoplakias) or of OSCC was considered inclusion
criteria.
DNA aneuploidy, patient age and tobacco smoke in OPMDs/OSCCs
PLOS ONE | https://doi.org/10.1371/journal.pone.0184425 September 6, 2017 2 / 12
Tissue samples for histological diagnosis and hr DNA-FCM were obtained from each
OPMD/OSCC by incisional biopsies and micro-biopsies (carried out by means of a curette) as
previously reported [26]. Tissue samples were also obtained by microbiopsies from mucosa at
a distance from co-existing OPMDs/OSCCs and characterized by visually normal appearing
mucosa. All patients were characterized by the presence of at least one OPMD/OSCC.
Patients with history of previous oropharyngeal cancer diagnosis were excluded from the
study.
Histological diagnosis was performed according to WHO guidelines by a specially trained
pathologist [26, 27].
Tissue samples for hr DNA-FCM analysis were either immediately processed or stored at
-20˚C and processed at a later time.
Nuclei extraction from oral microbiopsies, DAPI staining and hr
DNA-FCM analysis
DAPI (4’,6-diamidino-2-phenylindole) stained nuclei suspensions from tissue samples were
obtained as described by Otto et al. [28] with previously reported modifications [29]. DNA
content histograms were generated from DAPI stained nuclei suspensions by hr DNA-FCM
performed as previously reported [29] and analyzed to evaluate the DNA Index (DI).
When DNA aneuploid sublines (DI 6¼ 1) were detected, these were sorted using a Cyflow
Space FCM equipped with a PPCS unit (Partec GmbH, Muenster, Germany) at a purity of
about 99%.
Normal oral mucosae obtained from 3 healthy individuals used as normal controls showed
a DI = 1. In S1 Fig, we show the DNA content histograms as determined by hr DNA-FCM
analysis of these normal controls compared with 3 OPMDs/OSCCs samples with DI6¼1.
Representative pathological tissue sections for OPMD and OSCC are shown in S2 Fig.
DNA copy number analysis by aCGH
aCGH files were processed as described previously [13]. In brief, Agilent feature extraction
files were parsed in R, assessed for derivative log ratio spread (dLRS) using the function avail-
able in the supplementary material, and converted in to log2 ratio space. In general, files with a
dLRS> 0.35 were discarded, although we retained or discarded some samples based on visual
inspection of the karyogram plots. Probes were averaged over replicates, and used as input for
segmentation as follows: after probe value winsorization, data were segmented using the pcf or
the multipcf function available in the R/BioConductor package copynumber with default set-
tings [30]. Segments were considered aberrant if their log2 ratio values were above 0.32 for
copy gains and below -0.41 for copy losses, based on the assumption of a minimum cancer cell
fraction of 50% in the analyzed specimens and a mostly clonal population. For circular karyo-
grams and genome plots, we used the respective functions available in the copynumber pack-
age. To infer a measure of genomic instability for each patient, we first summed the number of
aberrant segments for each sample from each patient. Since multiple samples were subjected
to aCGH analysis for each patient, the average of aberrations per sample was used for further
analysis. We used the Fisher exact test for count data to assess whether genomic instability was
associated with ageing as a categorical parameter (older or younger than median) and smok-
ing. To assess whether statistically significant results were independently associated with geno-
mic instability, we fitted a multivariable linear model with the number of aberrations per
patients as a dependent variable, age, and smoking as categorical dependent variables. The
interaction of age and smoking with genomic instability was not modeled due to the relative
small sample size of our set. P values were all calculated using two-sided tests. All statistics
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were performed in the R environment for statistical computing and graphics. Metadata from
the 65 patients included in this aCGH study are available in S1 File. Raw and processed data
from OPMDs/OSCCs patients’ samples are available in GEO (http://www.ncbi.nlm.nih.gov/
geo/) under the accession number GSE66136.
Statistical analysis
Binary logistic regression analysis was performed to explore the influence of various patients’
characteristics on the dichotomous outcome, which is a DNA diploid (DI = 1) or a DNA aneu-
ploid status (DI6¼1).
When indicated, the two-tailed Mann–Whitney (MW) U test was applied to test differences
in age distribution between two independent groups of patients while the Kruskal-Wallis test
was applied to test differences in age distribution among more than two independent groups
of patients. To correct for multiple comparison, false discovery rates (FDR) q-values were cal-
culated as previously reported [31].
Current and former tobacco smokers’ patients were both included in the smokers’ patients
subgroup while the non-smokers’ subgroup included patients that never smoked.
Former and current drinkers were both included in the drinkers’ subgroup while occasional
drinkers were included with abstainers in the non-drinkers’ subgroup.
Patients with OPMDs in multiple oral subsites were represented by the OPMD with the
most severe histological diagnosis.
Results
Patients’ characteristics age distribution among patient subgroups
Patients’ characteristics are shown in Tables 1–3 and differences in age distribution among
patient subgroups are shown in Table 1.
Relationship between ploidy status, age, and smoke habit, in OPMDsa
and OSCCsb patients
The relationship of DNA aneuploiy (DI 6¼ 1), in all OPMDs/OSCCs, with age and tobacco
smoke habit, was analyzed by logistic regression. The presence or absence of DNA aneuploidy
was the response variable for the logistic regression. Age was taken as a covariate variable in
the model.
The risk of occurrence of DNA aneuploidy in OPMDs/OSCCs with each year increase in
age was 1.03 (P = 0.027) (Table 4).
When we examined the OPMDs/OSCCs from the non-smoker patients’ subgroup, the OR
of age increased to 1.12 (P<0.0005) (Table 4). On the contrary, for the smokers’ subgroup, we
could not find a significant association of DNA aneuploidy with age (OR 1.00, 95%CI 0.97–
1.03). Accordingly, the difference in ORs of age, between non-smokers and smokers, resulted
highly statistically significant (P = 0.006, Z test for OR difference).
According to Holgersson and coworkers [32], we preferred to run separate models for
smoker and non-smoker groups. In this case, the variance across the two different category
analyses is not a priori known to be homogeneous, and category-wise approach is invariant to
a possible difference in-group variances. However, the interaction term also reached statistical
significance for age and smoking status (OR = 1.097, P = 0.001), when added to the logistic
regression model performed on the “all patients” group.
It should be noticed that although limiting our logistic regression analysis to ND-OPMD
patients, we still found, a significant difference (P = 0.006) between the OR of age in non-
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smokers (1.13, 95%CI 1.04–1.24) and smokers (0.99, 95%CI 0.96–1.03). On the other hand, in
OSCC patients the difference between ORs for age in non-smokers and smokers did not reach
statistical significance (OR 1.07, P = 0.158 and OR 1.01, P = 0.674; Z-test P = 0.340). Among
non-smokers, we found that the median age of the patients with DNA aneuploid OPMDs
(74.31 years) was significantly higher compared to those with DNA diploid OPMDs (63.61
years) (Fig 1).
Notably, we found that smokers with DNA aneuploid OPMDs had a younger median age
of 14.23 years (Fig 1) with respect to non-smokers with DNA aneuploid OPMDs (Fig 1). Fur-
thermore, in OSCC patients, we observed that 30 out of 33 (90.9%) OSCCs were DNA aneu-
ploid among the non-smokers compared to only 21 out of 35 (60%) among the smokers (Fig
1). In this case the OR was 0.17 (P = 0.021) as estimated by logistic regression analysis
(Table 4).
Table 1. Patients’ characteristics and differences in age distribution among patient subgroups.
Patients’ data Number Median age in years (range)
Male 100 62.1
(18.5–87.8)
P = 0.002a
Female 120 67.4
(19.8–93.8)
Non-smokers 91 69.4
(18.5–93.8)
P = 0.002a
Smokers 129 62.9
(19.8–87.8)
ND-OPMDsb 126 63.1
(26.2–92.8)
P = 0.004c
D-OPMDsd 26
(17 mild, 7 moderate, 2 severe)
65.7
(18.5–93.8)
OSCCse 68 71.0
(19.8–90.6)
Single oral subsite OPMDs/OSCCs 158 66.5
(19.8–93.8)
P = 0.352a
Multiple oral subsite OPMDs/OSCCs 62 64.5
(18.5–87.3)
DNA diploid 125 62.9
(18.5–89.8)
P = 0.0001a
DNA aneuploid 95 70.6
(19.8–93.8)
aMann–Whitney (MW) U test.
bNon dysplastic oral potentially malignant disorders, ND-OPMDs.
cKruskal-Wallis test.
dDysplastic oral potentially malignant disorders, D-OPMDs.
eOral squamous cell carcinomas, OSCCs.
https://doi.org/10.1371/journal.pone.0184425.t001
Table 2. Patients’ tobacco consumption details (54 former and 76 current smokers).
Tobacco smoke free (in former smokers; months) Cigarette packs/day Cigarette packs/year Smoke duration (years)
Median 180 1 24 35
Minimum 2 1/20 1.5 3
Maximum 600 3 120 70
https://doi.org/10.1371/journal.pone.0184425.t002
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Table 4. Relationship between ploidy status, age, and smoke habit, in OPMDsa and OSCCsb patients.
DNA aneuploidy in patients with OPMDs or OSCCs Odds Ratio P-valuec Lower 95% Confidence interval Upper 95% Confidence interval
All patients
Age 1.03 0.027 1.00 1.05
OSCCs vs OPMDs 8.28 <0.0005 4.01 17.1
Multiple vs single oral subsite OPMDs/OSCCs 0.35 0.007 0.16 0.75
Smokers vs Non-smokers 0.73 0.397 0.35 1.51
Drinkers vs Non-drinkers 1.11 0.770 0.56 2.21
Gender (female vs male) 0.78 0.507 0.38 1.62
OPMD patients
Age 1.03 0.051 1.00 1.06
D-OPMDsd vs ND-OPMDse 3.08 0.017 1.22 7.76
Multiple vs single oral subsite OPMDs 0.21 0.008 0.07 0.67
Smokers vs Non-smokers 1.51 0.391 0.59 3.90
Drinkers vs Non-drinkers 1.19 0.693 0.51 2.78
Gender (female vs male) 0.77 0.568 0.32 1.87
OSCC patients
Age 1.03 0.201 0.98 1.08
Multiple vs single oral subsite OSCCs 0.55 0.391 0.14 2.13
Smokers vs Non-smokers 0.17 0.021 0.04 0.76
Drinkers vs Non-drinkers 0.72 0.617 0.20 2.63
Gender (female vs male) 1.03 0.973 0.24 4.39
Non-smoker patients
Age 1.12 <0.0005 1.05 1.19
OSCCs vs OPMDs 73.06 <0.0005 11.20 476.55
Multiple vs single oral subsite OPMDs/OSCCs 0.28 0.138 0.05 1.50
Drinkers vs Non-drinkers 1.15 0.883 0.19 7.09
Gender (female vs male) 0.41 0.371 0.06 2.93
Smoker Patients
Age 1.00 0.929 0.97 1.03
OSCCs vs OPMDs 4.21 0.002 1.72 10.27
Multiple vs single oral subsite OPMDs/OSCCs 0.24 0.005 0.09 0.65
Drinkers vs Non-drinkers 0.80 0.578 0.36 1.76
Gender (female vs male) 0.70 0.399 0.30 1.61
aOral potentially malignant disorders, OPMDs.
bOral squamous cell carcinomas, OSCCs.
cP- values <0.05 are in bold.
dDysplastic oral potentially malignant disorders, D-OPMDs.
eNon dysplastic oral potentially malignant disorders, ND-OPMDs.
https://doi.org/10.1371/journal.pone.0184425.t004
Table 3. Patients’ alcohol consumption details.
Alcohol Units/day
Median 1
Minimum 0.5
Maximum 8
https://doi.org/10.1371/journal.pone.0184425.t003
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Fig 1. Age distribution, tobacco smoke habit and DNA ploidy status in oral potentially malignant
disordes (OPMDs) and oral squamous cell carcinomas (OSCCs) patients. The bottom and the top of
each box show the first and third quartile while the line inside the box represents the median (second quartile).
The tips of the whiskers represent the minimum and the maximum data value. The number of patients for
each category is indicated at the bottom of the corresponding box. The boxes corresponding to DNA diploid
OPMDs/OSCCs are white while those corresponding to DNA aneuploid OPMDs/OSCCs have a striped
pattern. Significant (MW test) P-values (P < 0.05) are indicated. The FDR q-value method was applied for
multiple testing (n = 8) correction and the resulting q-values are indicated.
https://doi.org/10.1371/journal.pone.0184425.g001
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With regards to the relationship of DNA aneuploidy with histology and smoke habit, as
expected from our previous study [13], the odds ratio (OR) of the association of DNA aneu-
ploidy was statistically significant in D-OPMDs vs ND-OPMS and in OSCCs vs OPMDs in
our cohort of patients (Table 4). In both the non-smokers’ and smokers’ subgroups the associ-
ation of DNA aneuploidy with OSCCs was significantly greater than with OPMDs (Table 4).
However, this association was significantly higher in the non-smokers’ subgroup (Z test
P = 0.007).
In this study we also investigated the relationship between DNA aneuploidy, smoke and the
presence of OPMDs involving single or multiple anatomical subsite of the patients’ oral
mucosa. In our cohort of patients, in the OPMDs and in the smokers’ subgroup the OPMDs
involving a single subsite were significantly associated to DNA aneuploidy (P = 0.008 and
P = 0.002, respectively) (Table 4).
We also investigated the relationship between alcohol consumption and aneuploidy in our
dataset and did not find a statistically significant association (Table 4). Similarly, the gender
was never a significant confounding factor (Table 4).
Relationship between genomic aberrations, age, and smoke habit, in
OPMDs and OSCCs patients
To assess genomic aberrations and generate virtual karyotypes in our patient set, aCGH analy-
sis was performed on oral mucosa in a subset of 65 patients with OPMDs/OSCCs and in 2
healthy individual used as controls. DNA copy number gains and losses were detected in both
smokers and non-smokers OPMDs/OSCCs mucosae (S3 Fig) whereas neither gains nor losses
were detected in normal oral mucosa controls (S4 Fig). Furthermore, to assess the relationship
between genomic aberrations with age and smoking status, the mean number of genomic
aberrations (MNGA) was determined for each subject. We found a statistically significant
association between the MNGA per patient with age (22.2 in patients younger than median
age vs. 29.2, P = 0.0002, Fig 2A), but not with smoking habit (24.7 in nonsmokers vs. 26.7 in
smokers, Fig 2B). The association between MNGA and age remained significant by multiple
regression (β coefficient = 7.4, 95%CI = 1.6–13.2, P = 0.0186).
Discussion
The aim of this study was mainly to assess the relationship between aging, tobacco smoke and
DNA aneuploidy, determined by hr DNA-FCM, in OPMDs/OSCCs.
Our results showed a higher occurrence of both DNA aneuploidy and MNGA with patients’
age. In particular, among the non-smokers the association of patients’ age with DNA aneu-
ploid OPMDs/OSCCs was significantly higher compared to those with DNA diploid OPMDs/
OSCCs. This is in agreement with our previous study [25]. In addition, this observation was
strengthened by the logistic regression analysis, which confirmed the relationship between
DNA aneuploidy and age. It should be also noticed that this result did not depend from a dif-
ferent prevalence of OSCCs cases between the two patient subgroups. In fact, in our dataset
the number of OSCCs was lower in the non-smoker subgroup and no statistically significantly
difference in median age was found between non-smokers and smokers with DNA aneuploid
OSCCs. Furthermore, the detected relationship between DNA aneuploidy and age appeared
more pronounced in the non-smokers group when the analysis was limited to ND-OPMDs
patients.
Overall, our results support the hypothesis that the causes that generate DNA aneuploidy in
the oral mucosa are different between non-smokers and smokers. In particular, it appears that
DNA aneuploidy, patient age and tobacco smoke in OPMDs/OSCCs
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aging-related genotoxic mechanisms play a more important role in non-smokers while
smoke-related genotoxic damage is an additional factor involved in smokers.
Notably, we could not reveal differences in DNA aneuploidy occurrence between smokers
and non-smokers in our entire patient dataset, which appears in line with a recent cytological
study performed on normal mucosa [33]. Similarly, our aCGH analysis did not detect differ-
ences of MNGA in smokers compared to non-smokers OPMDs/OSCCs.
In the present study the association between DNA aneuploidy and OSCCs was much higher
in the non-smokers’ group. This result suggests that while age-related CIN may be the main
genetic mechanism that drives cancer development of OPMDs in non-smokers, a substantial
amount of OPMDs in smokers progress to cancer via CIN-independent mechanisms, which
include gene mutations. In our view this result may have potential application in clinical prac-
tice. In particular, DNA diploid OPMDs may be considered at lower risk of cancerization than
DNA aneuploid ones in non-smokers but not in smokers.
On the basis of the relationship between DNA aneuploidy and single site OPMDs here
reported, we suggest that while in smokers OPMDs involving single oral subsites may progress
to cancer through CIN-related mechanisms, those that involve multiple oral subsites may
progress mainly through CIN-unrelated mechanisms.
Our study also showed that in our dataset neither alcohol consumption nor gender were
confounding factors.
Conclusions
The present study shows for the first time a significant relationship between aging and DNA
aneuploidy in OPMDs and between tobacco smoke and early appearance of DNA aneuploidy
in OPMDs. However, as these relationships have an OR close to 1, further studies are required
to establish whether they are of wide general validity.
Fig 2. Mean number of genomic aberrations (MNGA) per patient and age or smoking status in oral potentially malignant disordes
(OPMDs) and oral squamous cell carcinomas (OSCCs) patients. The average number of aberrations per patient is represented as gray
dots superimposed over boxes. These present a thick horizontal line indicating the median number per group, and delimitate the 25th and
75th percentile, while whiskers show the 95% confidence interval. A) average number of aberrations per patients’ age; B) average number of
aberrations per patients’ smoking habit.
https://doi.org/10.1371/journal.pone.0184425.g002
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Supporting information
S1 Fig. DNA histograms obtained by high resolution DNA flow cytometry from oral
mucosa. X axes show DNA content; Y axes show number of nuclei. A) Subject Ctr1A normal
mucosa; B) Subject Ctr2A normal mucosa; C) Subject Ctr7B normal mucosa; D) Pt111B ton-
gue OPMD; E) Pt108B tongue OSCC; F) Pt90B tongue OSCC. DNA Diploid (DI = 1.0) and
DNA aneuploid (DI6¼1) peaks are indicated.
(TIF)
S2 Fig. Representative pathological tissue sections. Non-dysplastic OPMD (A), OPMD with
mild-moderate dysplasia (B), OSCC (C).
(TIF)
S3 Fig. Circular karyograms obtained from aCGH data. In clockwise direction, the propor-
tion of gained (red) or lost (steel blue) regions is plotted over the corresponding chromosomes.
The higher the bar over a given region, the more frequent the aberration. A) Non-smokers; B)
Smokers.
(TIF)
S4 Fig. Genome plots. Segments (thick red line) are plotted over the individual probe values
in log2 ratio space; horizontal black lines represent the threshold for gain (0.32) and loss
(-0.41) assuming a fully clonal sample with 50% of cancerous cells and one copy gain or loss.
No losses or gains exceeding such cutoffs can be observed in the two healthy control samples
represented. Small red stars represent probes considered as outliers after winsorization and
not used for segment computation. A) Normal control sample Ctr1A_1; B) normal control
sample Ctr7B_1. On the top of each plot the aCGH raw file ID is shown (see GEO Accession
Number in Materials and methods).
(TIF)
S1 File. Metadata from the 65 patients included in this aCGH study.
(XLSX)
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